Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
Sample Size Calculation01:19

Sample Size Calculation

3.2K
Knowledge of the sample size is the first requirement to conduct random sampling or an experiment. The sample size is the total number of units, observations, or groups (in some cases) used to get the data to estimate a population parameter. As the name suggests, the sample size is that of the sample drawn from the population and differs from the population size.
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
3.2K
Randomized Experiments01:13

Randomized Experiments

6.7K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
6.7K
Regression Toward the Mean01:52

Regression Toward the Mean

6.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

82
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
82
Censoring Survival Data01:09

Censoring Survival Data

57
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
57

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SECRETS: Subject-efficient clinical randomized controlled trials using synthetic intervention.

Contemporary clinical trials communications·2024
Same author

Nanomedicines for the management of diabetic nephropathy: present progress and prospects.

Frontiers in endocrinology·2023
Same author

IGF-1 and GLP-1 signaling: potential therapeutic target for neurological disorders - correspondence.

Annals of medicine and surgery (2012)·2023
Same author

DINI: data imputation using neural inversion for edge applications.

Scientific reports·2022
Same author

Genome editing technologies, mechanisms and improved production of therapeutic phytochemicals: Opportunities and prospects.

Biotechnology and bioengineering·2022
Same author

Exploring the role of antibiotics and steroids in managing respiratory diseases.

Journal of biochemical and molecular toxicology·2022

Related Experiment Video

Updated: May 30, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

423

TAD-SIE: sample size estimation for clinical randomized controlled trials using a Trend-Adaptive Design with a

Sayeri Lala1, Niraj K Jha2

  • 1Department of Electrical and Computer Engineering, Princeton University, Princeton, 08544, NJ, USA. slala@princeton.edu.

Trials
|January 29, 2025
PubMed
Summary

A new algorithm, Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator (TAD-SIE), improves clinical trial success rates by optimizing sample size estimation. This method enhances power and reduces failure in Phase-3 drug development trials.

Keywords:
Adaptive designClinical randomized controlled trialsCounterfactual estimationCrossover designSample size estimationSynthetic intervention

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Related Experiment Videos

Last Updated: May 30, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

423
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Drug Development

Background:

  • Phase-3 clinical trials are crucial for drug approval, providing high-level evidence on safety and effectiveness.
  • A significant challenge in these trials is inadequate sample size, leading to a 30-40% failure rate.
  • Inaccurate initial estimates of average treatment effects contribute to insufficient sample sizes.

Purpose of the Study:

  • To address the obstacle of inadequate sample sizes in Phase-3 clinical trials.
  • To introduce a novel algorithm, Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator (TAD-SIE), to enhance trial design and power.
  • To improve the accuracy of sample size estimation for drug development.

Main Methods:

  • The TAD-SIE algorithm powers parallel-group randomized controlled trials (RCTs) using a novel trend-adaptive design (TAD) and synthetic intervention (SI).
  • SI is employed to estimate individual treatment effects, simulating a cross-over design to improve trial power within sample size constraints.
  • A new TAD tailored for SI is implemented, allowing for adaptive sample size increases across iterations while controlling significance levels and incorporating futility stopping.

Main Results:

  • On a real-world Phase-3 RCT, TAD-SIE achieved operating points with 63% to 84% power and a 3% to 6% significance level.
  • Baseline algorithms, in contrast, achieved a maximum of 49% power and a 6% significance level.
  • The results demonstrate superior performance of TAD-SIE in achieving target operating points for clinical trials.

Conclusions:

  • TAD-SIE is a superior trend-adaptive design method for clinical trials with rapidly measurable outcomes due to its sequential nature.
  • The framework offers a valuable tool for researchers aiming to utilize the synthetic intervention algorithm in study design.
  • This approach can help practitioners overcome sample size limitations and improve the success rate of drug development trials.